Cagrilintide vs Semaglutide for appetite
Short answer: For appetite, more users report improvement with Cagrilintide — 100% of 8 reports, versus 80% of 70 for Semaglutide.
Cagrilintide has 9 meta-analyses and 15 randomized trials on PubMed; Semaglutide has 421 and 307.
Based on 32 reports about Cagrilintide and 330 about Semaglutide. Not medical advice.
| Cagrilintide Peptide | Semaglutide Medication | |
|---|---|---|
| Users say it helped | 82%helped11 reports · few reports | 64%helped228 reports · high confidence |
| Verdict | Mostly positive | Mostly positive |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 9 / 15 | 421 / 307 |
| Mainly used for | ||
| Weight loss % reporting improvement | 100% (7) | 85% (138) |
| Appetite % reporting improvement | 100% (8) | 80% (70) |
| Energy % reporting improvement | — | 39% (23) |
| Mood % reporting improvement | — | 27% (11) |
| Blood sugar % reporting improvement | — | 90% (10) |
| Common side effects | fatigue, appetite loss, depressive episode | nausea, fatigue, stomach issues, constipation |
| Typical dose reported | Not listed | Not listed |
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events.
BMJ, 2024 ↗“Cagri was a game changer for me. I added 1mg and thats been more than enough.”
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate